Biohit Oyj revised earnings guidance for the year 2022. For the year, the company revises its EBIT to be positive in 2022 (2021: EUR -1.5 million). The previous guidance for 2022, issued on March 30, 2022.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.985 EUR | -1.24% | -1.73% | +5.31% |
Apr. 15 | Faron Pharmaceuticals reappoints former finance chief on interim basis | AN |
Feb. 14 | Biohit Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.31% | 32.57M | |
+9.51% | 8.03B | |
-8.67% | 2.82B | |
+5.40% | 2.1B | |
-25.84% | 1.13B | |
-10.46% | 828M | |
-22.21% | 764M | |
-14.18% | 745M | |
-56.76% | 684M | |
-23.48% | 682M |
- Stock Market
- Equities
- BIOBV Stock
- News Biohit Oyj
- Biohit Oyj Revises Earnings Guidance for the Year 2022